ICORD 2010 will celebrate its 6th edition this year in Buenos Aires. The main aim of the conference is to build up constructive international collaborations in orphan products development, information development and dissemination activities, which will result in diagnostic and treatment advances for patients who have rare diseases. The program will have separate areas including rare diseases research tools, patient registries and bio-specimen repositories, linking the academic research community to industry, genetic testing for rare diseases, patient and family needs across the lifespan, gaining regulatory approval, recruiting patients for clinical research studies and expanding geographical borders to include many other nations that were not present at these previous meetings. All the topics will be covered by plenary presentations and discussions on various advances made in the field of international collaboration on rare diseases.
The ICORD conference will cover the topics mentioned below:
- Rare Diseases Projects to Link Discoveries from Academic Institutions with the Pharmaceutical, Biotechnology, and Medical Devices Industries
- Efforts to Link Patients to Research Studies and Treatment Centers of Excellence
- Accessibility Needs to Orphan Products for Diagnosis and Treatments in Developing Countries
- New National Programs Introduced or Planning to be Developed in the Near Future
- Rare Diseases and Orphan Product Activities in Latin America and Caribbean Countries.
- Globalization of Rare Diseases Activities and Building on the Previous Experiences of the Countries with Active Programs
- Establishing Rare Diseases as a Public Health Priority through National Plans and Government Emphasis
- WHO procedures for the International Classification of Diseases and the New Initiative to Provide an Emphasis on Rare Diseases
- Model Programs of Patient and Family Care to Provide Better Access to Earlier Diagnosis and Treatments
- Experiences in Introducing and Providing Access To Recently Approved Orphan Products and the Re-Profiling of Approved Products,
- Bioethics in Vulnerable Populations and Access to Appropriate Diagnosis and Treatments
- Common Health and Social Aspects Between Rare and Neglected Diseases of Interest in Developing Countries
- Company representatives